Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
The study will include about 500 patients with endometrial cancer resistant to platinum/taxane-based chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Göttingen, Germany
Halle, 06097, Germany
Regensburg, Germany
Cluj Npaoca, 400015, Romania
Saint Petersburg, 191014, Russia
Saint Petersburg, 198255, Russia
Plyuty, Kyiv Oblast 08720, Ukraine
Dnipro, 49102, Ukraine